Oncology · Metastatic Colorectal and Gastric CancerTrial Updateclinicalmid-term

JNJ-89402638 Phase 2 Study Initiated for Metastatic Colorectal and Gastric Cancers

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Janssen Research & Development, LLC2 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/22/2026, 6:31:44 AM

Assessment confidence: 63% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of the Phase 2 study for JNJ-89402638 is significant as it could redefine treatment protocols for metastatic colorectal and gastric cancers. Positive outcomes may enhance Janssen's competitive positioning against established therapies, particularly bevacizumab. Regulatory context from FDA (Verified Clinical Benefit | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 12 ranked evidence items (6 high-relevance).

Strategic Assessment

The outcomes could influence treatment protocols and competitive positioning against existing therapies like bevacizumab. The strongest clinical anchor is A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression (ClinicalTrials.gov), patient population match (metastatic). In colorectal cancer, 3 regulatory and 0 competitive items passed relevance filtering for Janssen Research & Development, LLC.

Competitive Pressure

The most relevant competitive pressure comes from This study positions Janssen's JNJ-89402638 as a potential competitor in the treatment landscape for metastatic colorectal and gastric cancers..

Regulatory Outlook

Regulatory risk is concentrated around Verified Clinical Benefit | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). The study's outcomes will be critical for determining the safety profile and optimal dosing, which are essential for future regulatory submissions and approvals.

Key Risks

Elevated medium regulatory exposure for Janssen Research & Development, LLC could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful trial results could lead to increased market share for JNJ-89402638, potentially impacting revenue streams and competitive dynamics in the oncology market.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Upside for Janssen Research & Development, LLC may improve if Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma (ClinicalTrials.gov) delivers favorable follow-through.
The outcomes could influence treatment protocols and competitive positioning against existing therapies like bevacizumab.

What Would Change This Assessment

This becomes more urgent if Monitor results for RP2D determination and safety outcomes, as well as potential combination therapy efficacy.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Verified Clinical Benefit | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
Other | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression
ClinicalTrials.govmedium relevance
Patient population match (metastatic)
FDA document
View source
Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
ClinicalTrials.govmedium relevance
Patient population match (metastatic)
FDA document
View source
Study Evaluating Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck
ClinicalTrials.govmedium relevance
Patient population match (metastatic)
FDA document
View source
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

No evidence in this category.

Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Entity match (metastatic colorectal cancer)
FDA document
View source
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Patient population match (metastatic)
FDA document
View source
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Association of Intraoperative Fluid Exposure with Time to First Flatus after Laparoscopic Radical Resection for Colorectal Cancer: A Retrospective Cohort Study.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Cost-effectiveness of multitarget stool DNA testing for colorectal cancer screening in Chinese primary healthcare settings: a modelling study.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Intramuscular patient-derived xenografts achieve high engraftment rates in gastric cancer: implications for pharmacodynamic testing and genomic biomarker discovery.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Janssen Research & Development, LLC
JNJ-89402638
bevacizumab
metastatic colorectal cancer
metastatic gastric cancer

Commercial impact

medium

Successful trial results could lead to increased market share for JNJ-89402638, potentially impacting revenue streams and competitive dynamics in the oncology market.

Regulatory impact